Survival of cervical cancer patients in Germany in the early 21st century: A period analysis by age, histology, and stage

Acta Oncologica

Volumn 51, Issue 7, 2012, Pages 915-921

  Chen, Tianhui ^a,b   Jansen, Lina ^b   Gondos, Adam ^b   Emrich, Katharina ^c   Holleczek, Bernd ^d   Luttmann, Sabine ^e   Waldmann, Annika ^f   Brenner, Hermann ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c University Medical Center   (Germany)

^d SAARLAND CANCER REGISTRY   (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

^f UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; FEMALE; GERMANY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 84866409997     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.708105     Document Type: Article

References (46)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Adami HO, Ponten J, Sparen P, Bergstr öm R, Gustafsson L, Friberg LG. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. 1960-1984. Cancer 1994; 73: 140-7. (Pubitemid 24012734)
3. Arbyn M, Rebolj M, De Kok I M, Fender M, Becker N, O'Reilly M, et al. The challenges of organising cervical screening programmes in the 15 old member states of the European Union. Eur J Cancer 2009; 45: 2671-8.
4. IARC. Cervix Cancer Screening.Lyon: IARC Press; 2005.
5. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-62. (Pubitemid 35446606)
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide. Lyon, France: International Agency for Research on Cancer: IARC CancerBase No. 10; 2010.
7. Anttila A, Ronco G. D escription of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009; 45: 2685-708.
8. Arbyn M, Autier P, Ferlay J. B urden of cervical cancer in the 27 member states of the European Union: Estimates for 2004. Ann Oncol 2007; 18: 1423-5. (Pubitemid 47305020)
9. Becker N. E pidemiological aspects of cancer screening in Germany. J Cancer Res Clin Oncol 2003; 129: 691-702. (Pubitemid 38002300)
10. Schenck U, von Karsa L. C ervical cancer screening in Germany. Eur J Cancer 2000; 36: 2221-6.
11. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-96. (Pubitemid 47321601)
12. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45: 931-91.
13. Brenner H, Stegmaier C, Ziegler H. L ong-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 2005; 16: 981-6. (Pubitemid 40903926)
14. Brenner H, Gefeller O. A n alternative approach to monitoring cancer patient survival. Cancer 1996; 78: 2004-10. (Pubitemid 26360586)
15. Brenner H, Gefeller O, Hakulinen T. P eriod analysis for 'u pto-date ' cancer survival data: Theory, empirical evaluation, computational realisation and applications. Eur J Cancer 2004; 40: 326-35. (Pubitemid 38121268)
16. Brenner H, Hakulinen T. U p-to-date and precise estimates of cancer patient survival: Model-based period analysis. Am J Epidemiol 2006; 164: 689-96. (Pubitemid 44453498)
17. Gondos A, Bray F, Brewster DH, Coebergh JW, Hakulinen T, Janssen-Heijnen ML, et al. Recent trends in cancer survival across Europe between 2000 and 2004: A model-based period analysis from 12 cancer registries. Eur J Cancer 2008; 44: 1463-75.
18. Hiripi E, Gondos A, Emrich K, Holleczek B, Katalinic A, Luttmann S, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol 2012; 23: 472-9.
19. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L H, Parkin DM, et al. International classifi cation of diseases for oncology, 3rd ed. Geneva: World Health Organization; 2000.
20. Kosary C L. Cancer of the cervix uteri. In: Gloeckler RLA, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER Survival Monograph: Cancer survival among adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. SEER Program, NIH Pub. No. 07-6215. Bethesda, MD: National Cancer Institute; 2007. p. 111-22.
21. Dudeck J, Wagner G, Grundmann E, Hermanek P. Basisdokumentation f ü r Tumorkranke, Prinzipien und Verschl ü sselungsanweisungen f ü r Klinik und Praxis, 5. Aufl age; Zuckschwerdt Verlag: 1999.
22. Brenner H, Soderman B, Hakulinen T. U se of period analysis for providing more up-to-date estimates of long-term survival rates: Empirical evaluation among 370,000 cancer patients in Finland. Int J Epidemiol 2002; 31: 456-62. (Pubitemid 34537812)
23. Brenner H, Hakulinen T. U p-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol 2002; 20: 826-32. (Pubitemid 34111392)
24. Ederer F, Axtell L M, Cutler S J. T he relative survival rate: A statistical methodology. Natl Cancer Inst Monogr 1961; 6: 101-21.
25. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Bethesda (MD): National Cancer Institute; 1959.
26. Corazziari I, Quinn M, Capocaccia R. S tandard cancer patient population for age standardising survival ratios. Eur J Cancer 2004; 40: 2307-16. (Pubitemid 39348882)
27. Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patient survival. Eur J Cancer 2002; 38: 690-5. (Pubitemid 34251393)
28. Gatta G, Capocaccia R, Hakulinen T, Sant M, Verdecchia A, De Angelis G, et al. Variations in survival for invasive cervical cancer among European women, 1978-89. EUROCARE Working Group. Cancer Causes Control 1999; 10: 575-81.
29. Bielska-Lasota M, Inghelmann R, Poll-Franse L, Capocaccia R. Trends in cervical cancer survival in Europe, 1983-1994: A population-based study. Gynecol Oncol 2007; 105: 609-19. (Pubitemid 46734180)
30. Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Allemani C, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 2009; 45: 1042-66.
31. Vrdoljak E, Hamm W. C urrent state-of-the-art of concomitant chemoradiation in cervical carcinomas. Eur J Gynaecol Oncol 2003; 24: 475-9. (Pubitemid 37462564)
32. Green J A, Kirwan J M, Tierney J F, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 2001; 358: 781-6. (Pubitemid 32868726)
33. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; (3): CD002225.
34. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: A systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-12.
35. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: Individual patient data meta-analysis. Cochrane Database Syst Rev 2010; (1): CD008285.
36. Pearcey R, Miao Q, Kong W, Zhang-Salomons J, Mackillop WJ. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: Results of a population-based cohort study. J Clin Oncol 2007; 25: 2383-8. (Pubitemid 46999208)
37. Kunos C, Tian C, Waggoner S, Rose P G, Lanciano R. Retrospective analysis of concomitant Cisplatin during radiation in patients aged 55 years or older for treatment of advanced cervical cancer: A gynecologic oncology group study. Int J Gynecol Cancer 2009; 19: 1258-63.
38. Ruckinger S, Tauscher M, Redel R, Munte A, Walchner-Bonjean M, Hess J, et al. Participation in cervical cancer screening by age and region-a cohort study with a 3 1/2 year follow-up on 2,223,135 women in Bavaria. Gesundheitswesen 2008; 70: e17-21.
39. B alducci L. G eriatric oncology: Challenges for the new century. Eur J Cancer 2000; 36: 1741-54. (Pubitemid 30639493)
40. Kosary CL. F IGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: An analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 1994; 10: 31-46. (Pubitemid 24053286)
41. zur Hausen H. P apillomaviruses in the causation of human cancers-a brief historical account. Virology 2009; 384: 260-5.
42. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. (Pubitemid 29406813)
43. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen A M, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
44. Lai C H, Chang C J, Huang H J, Hsueh S, Chao A, Yang J E, et al. Role of human papillomavirus genotype in prognosis of early-stage cervical cancer undergoing primary surgery. J Clin Oncol 2007; 25: 3628-34. (Pubitemid 47376606)
45. B urger R A, Monk B J, Kurosaki T, Anton-Culver H, Vasilev SA, Berman ML, et al. Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst 1996; 88: 1361-8. (Pubitemid 26329753)
46. Eisemann N, Waldmann A, Katalinic A. I mputation of missing values of tumour stage in population-based cancer registration. BMC Med Res Methodol 2011; 11: 129.